SeaStar Medical Q1 revenue $0.5M, up 69% YoY; net loss $3.5M

SeaStar Medical Holding Corp

Net revenue of $0.5M from QUELIMMUNE sales, vs $0.3M in Q1 2025.
Net loss $3.5M ($0.90/share) vs $3.8M ($4.38/share) a year ago.
Cash $9.3M at March 31, down from $12.0M at Dec 31, 2025.
NEUTRALIZE-AKI trial enrolled 198 of 339 patients; PMA submission efforts initiated.
Added 7 children’s hospitals, now 17 total, targeting 15 more in 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SeaStar Medical Holding Corp reported the three months ended March 31, 2026 results: revenue $0.5 million.

Period: the three months ended March 31, 2026
Revenue: $0.5 million
Result: reported results

Exact text from the filing

from top-rated children’s hospitals, bringing the total customer base to 17 and building increased depth in customer orders. This led to first quarter 2026 net revenue of $0.5 million for QUELIMMUNE product sales, an increase of 69% versus the first quarter of 2025. ● Advanced enrollment in the NEUTRALIZE-AKI pivotal trial that is evaluating the Selective

View on SEC.gov

Browse all earnings releases →

SeaStar Medical Holding Corp filing history →

Source: SEC EDGAR

accession 0001437749-26-016726

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.